Atrial natriuretic factor (1-28) (rat)Endogenous peptide regulating blood pressure CAS# 88898-17-3 |
2D Structure
- sitaxsentan
Catalog No.:BCC1951
CAS No.:184036-34-8
- Zibotentan (ZD4054)
Catalog No.:BCC2524
CAS No.:186497-07-4
- Atrasentan hydrochloride
Catalog No.:BCC1380
CAS No.:195733-43-8
- Avosentan
Catalog No.:BCC1387
CAS No.:290815-26-8
- Macitentan
Catalog No.:BCC1142
CAS No.:441798-33-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 88898-17-3 | SDF | Download SDF |
PubChem ID | 16132362 | Appearance | Powder |
Formula | C128H205N45O39S2 | M.Wt | 3062.43 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | Atrial Natriuretic Peptide (1-28) (rat) | ||
Solubility | H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: 3. Recommended solution: | ||
Sequence | SLRRSSCFGGRIDRIGAQSGLGCNSFRY (Modifications: Disulfide bridge between 7 - 23) | ||
SMILES | CCC(C)C(C(=O)NCC(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CO)C(=O)NCC(=O)NC(CC(C)C)C(=O)NCC(=O)NC(CS)C(=O)NC(CC(=O)N)C(=O)NC(CO)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCNC(=N)N)C(=O)NC(CC2=CC=C(C=C2)O)C(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(=O)O)NC(=O)C(C(C)CC)NC(=O)C(CCCNC(=N)N)NC(=O)CNC(=O)CNC(=O)C(CC3=CC=CC=C3)NC(=O)C(CS)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CO)N | ||
Standard InChIKey | BABRMHJHAGFVGO-BRTFOEFASA-N | ||
Standard InChI | InChI=1S/C128H207N45O39S2/c1-10-64(7)99(121(209)151-52-94(183)152-66(9)101(189)156-77(36-37-91(130)180)109(197)167-85(56-175)105(193)150-53-96(185)154-78(43-62(3)4)103(191)149-54-97(186)155-89(60-213)119(207)164-82(48-92(131)181)114(202)169-86(57-176)116(204)163-81(46-68-25-16-13-17-26-68)113(201)159-74(29-20-40-144-126(136)137)107(195)166-84(123(211)212)47-69-32-34-70(179)35-33-69)172-111(199)76(31-22-42-146-128(140)141)160-115(203)83(49-98(187)188)165-122(210)100(65(8)11-2)173-110(198)72(27-18-38-142-124(132)133)153-95(184)51-147-93(182)50-148-104(192)80(45-67-23-14-12-15-24-67)162-120(208)90(61-214)171-118(206)88(59-178)170-117(205)87(58-177)168-108(196)75(30-21-41-145-127(138)139)157-106(194)73(28-19-39-143-125(134)135)158-112(200)79(44-63(5)6)161-102(190)71(129)55-174/h12-17,23-26,32-35,62-66,71-90,99-100,174-179,213-214H,10-11,18-22,27-31,36-61,129H2,1-9H3,(H2,130,180)(H2,131,181)(H,147,182)(H,148,192)(H,149,191)(H,150,193)(H,151,209)(H,152,183)(H,153,184)(H,154,185)(H,155,186)(H,156,189)(H,157,194)(H,158,200)(H,159,201)(H,160,203)(H,161,190)(H,162,208)(H,163,204)(H,164,207)(H,165,210)(H,166,195)(H,167,197)(H,168,196)(H,169,202)(H,170,205)(H,171,206)(H,172,199)(H,173,198)(H,187,188)(H,211,212)(H4,132,133,142)(H4,134,135,143)(H4,136,137,144)(H4,138,139,145)(H4,140,141,146)/t64-,65-,66-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,83-,84-,85-,86-,87-,88-,89-,90-,99-,100-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Endogenous peptide produced by the heart; involved in blood pressure regulation. Produces natriuresis, diuresis and vasorelaxation in vivo. |
Atrial natriuretic factor (1-28) (rat) Dilution Calculator
Atrial natriuretic factor (1-28) (rat) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Inulanolide A
Catalog No.:BCN3705
CAS No.:888941-86-4
- Fosinopril sodium
Catalog No.:BCC2141
CAS No.:88889-14-9
- Sprengerinin A
Catalog No.:BCN6658
CAS No.:88866-99-3
- Adrenorphin, Free Acid
Catalog No.:BCC1011
CAS No.:88866-92-6
- Sprengerinin C
Catalog No.:BCN6657
CAS No.:88861-91-0
- 11,12-De(methylenedioxy)danuphylline
Catalog No.:BCN4436
CAS No.:888482-17-5
- Ganetespib (STA-9090)
Catalog No.:BCC2336
CAS No.:888216-25-9
- Galanin (porcine)
Catalog No.:BCC5960
CAS No.:88813-36-9
- Gambogoic acid B
Catalog No.:BCN7936
CAS No.:887923-50-4
- Isogambogenic acid
Catalog No.:BCN3076
CAS No.:887923-47-9
- Gaudichaudic acid
Catalog No.:BCN3071
CAS No.:887923-46-8
- Bafetinib (INNO-406)
Catalog No.:BCC4036
CAS No.:887650-05-7
- Bafilomycin A1
Catalog No.:BCC3914
CAS No.:88899-55-2
- Mogroside V
Catalog No.:BCN1036
CAS No.:88901-36-4
- Mogroside IIIe
Catalog No.:BCN7924
CAS No.:88901-37-5
- Mogroside IIe
Catalog No.:BCN3168
CAS No.:88901-38-6
- Mogroside IVa
Catalog No.:BCN3165
CAS No.:88901-41-1
- Mogroside III-A1
Catalog No.:BCN3170
CAS No.:88901-42-2
- Mogroside III-A2
Catalog No.:BCN7925
CAS No.:88901-43-3
- Mogroside II-A1
Catalog No.:BCN7926
CAS No.:88901-44-4
- Mogroside II-A2
Catalog No.:BCN3180
CAS No.:88901-45-5
- (-)-Xestospongin C
Catalog No.:BCC7002
CAS No.:88903-69-9
- Mogroside IVe
Catalog No.:BCN3166
CAS No.:88915-64-4
- Mogrol
Catalog No.:BCN8446
CAS No.:88930-15-8
The atrial natriuretic peptide: a changing view.[Pubmed:11677356]
J Hypertens. 2001 Nov;19(11):1923-31.
The atrial natriuretic peptide (ANP), a component of the natriuretic peptide family, was discovered in 1981 when de Bold and his coworkers observed a natriuretic effect induced by infusion of atrial extracts in rats. Subsequently, an impressive amount of research has been carried out in order to identify the structure of the active peptide and its receptors, to characterize the biological functions of ANP and its involvement in the pathophysiology of diseases and, finally, its direct contributory role in the pathogenesis of some cardiovascular disorders. ANP plays a key role in the regulation of salt and water balance, as well as of blood pressure homeostasis. In addition, ANP is involved in the pathophysiology of hypertension and heart failure, and exerts a cellular antiproliferative effect in the cardiovascular system. More recently, a direct contributory role of ANP in the development of hypertension and of cerebrovascular disorders has been suggested by the use of molecular genetic approaches. Therefore, our understanding of the pathophysiologic relevance of ANP has changed over time, finally leading to the identification of ANP as a potential determinant of cardiovascular diseases, rather than as a simple marker of cardiac and vascular dysfunctions. This novel view of ANP may open interesting research pathways.
Atrial natriuretic factor (auriculin): structure and biological effects.[Pubmed:2941526]
J Clin Hypertens. 1985 Jun;1(2):187-98.
Atrial natriuretic factor (ANF) is a recently discovered peptide present in secretory granules specifically found in atrial muscle cells. Multiple structurally related peptides have been isolated from atrial tissues, all of which are derived from a common 152-amino-acid precursor. ANF induces profound natriuresis and diuresis in experimental animals and also causes relaxation of precontracted vascular smooth muscle. ANF has striking renal hemodynamic actions (most consistently an increased glomerular filtration rate), which probably explain its natriuretic effects. ANF also can inhibit renin secretion in vivo and causes direct inhibition of basal and stimulated aldosterone production. It lowers arterial blood pressure, probably reflecting in part its vasorelaxant actions, and this effect is particularly marked in renin-dependent (and possibly other vasoconstricted) models of hypertension. Although the exact structure and regulation of the presumed circulating form(s) of ANF remain to be clarified, available information suggests that it may be a new, previously unrecognized factor in the regulation of fluid volume and renal and cardiovascular function.
Atrial natriuretic factor: a hormone produced by the heart.[Pubmed:2932797]
Science. 1985 Nov 15;230(4727):767-70.
Systematic studies on the significance of the secretory-like morphological characteristic of cardiac atrial muscle cells of mammals led to the finding that these cells produce a polypeptide hormone. This hormone, described in 1981 as atrial natriuretic factor (ANF), is diuretic (natriuretic), hypotensive, and has an inhibitory effect on renin and aldosterone secretion. Thus, ANF probably intervenes in the short- and long-term control of water and electrolyte balance and of blood pressure. Phylogenetically, ANF appears early, suggesting different functions for this peptide in accordance with each species' environment. Knowledge of the properties of the hormone should provide insights into the pathophysiology of important clinical entities and lead to the development of new pharmaceutical products.